Drug intelligence / Profile preview

acetaminophen + dextromethorphan hydrobromide + doxylamine succinate

Development stage
Unknown
Lead developer
Perrigo
Modality
Small Molecules
Administration
Oral
01

Overview

GoodSense NightTime Cold & Flu Multi Symptom is an over-the-counter (OTC) combination medication developed by Perrigo under the GoodSense brand. It is formulated to provide temporary relief from multiple symptoms associated with the common cold and influenza, specifically designed for nighttime use. The product contains three active ingredients: acetaminophen, which acts as an analgesic and antipyretic to reduce pain and fever; dextromethorphan hydrobromide, an antitussive that suppresses the cough reflex; and doxylamine succinate, a sedating antihistamine that relieves runny nose and sneezing while facilitating sleep. As a generic equivalent to brand-name products like NyQuil, it is widely used for managing nocturnal respiratory tract symptoms.

Brand names
GoodSense NightTime Cold & Flu Multi SymptomGoodSense NightTime Cold & Flu
02

Targets

HRH1 (Histamine H1 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)mAChR (Muscarinic acetylcholine receptors)COXNMDAR (Glutamate receptor ionotropic, NMDA)Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on acetaminophen + dextromethorphan hydrobromide + doxylamine succinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetaminophen + dextromethorphan hydrobromide + doxylamine succinate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call